Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Scientists at the University of Bonn have shown in mice that excess pounds can simply be melted away by converting unwanted white fat cells into energy-consuming brown slimming cells.
A new treatment may diminish a dangerous side effect associated with transfusions of red blood cells (RBCs) known as pulmonary hypertension, an elevated blood pressure in the lungs and heart that can lead to heart failure, suggests a new study published in the November issue of Anesthesiology, the peer-reviewed medical journal of the American Society of Anesthesiologists.
This expedition was a part of our clinical collaboration with the Mayo Clinic. In short, this particular study focused on the effect of altitude and aging on heart and lung function.
A weight-loss drug dampened the response to food cues in regions of the brain associated with attention and emotion, leading to decreases in caloric intake, weight and body mass index (BMI), a team led by scientists at Beth Israel Deaconess Medical Center reported.
The European Society of Cardiology has launched a novel position paper, under the auspices of its Committee for Practice Guidelines, on tackling the cardiac toxicity of anticancer therapies. The cardio-oncology paper is published online today in European Heart Journal and on the ESC Website.
Pulmonology and genetics experts from two Utah healthcare organizations have collaboratively developed a new diagnostic genomic testing method for a rare form of pulmonary hypertension caused by a genetic mutation they discovered three years ago.
In contrast to the general belief that the airways of an infant are sterile until after birth, University of Alabama at Birmingham researchers and colleagues have found that the infant airway is already colonized with bacteria or bacterial DNA when a baby is born -- and this is true for infants born as early as 24 weeks gestation.
In our latest report – The Battle for Breath – the impact of lung disease in the UK, figures suggest that 1 in 5 (around 12.7 million) have been diagnosed with a lung condition in the UK. If you’re over the age of 70, this rises to 1 in 3.
The number of patients hospitalized with HFpEF is now comparable to those with traditional heart failure with a reduced ejection fraction (HFrEF) and is projected to exceed that of HFrEF within the next few years.
The University of Alabama at Birmingham is the only university to be awarded grants in all three perinatal networks from the Eunice Kennedy Shriver National Institute of Child Health and Human Development to improve maternal and infant health.
Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.
Hepatoma-derived growth factor predicts disease severity and survival in patients with pulmonary arterial hypertension, showing some possible clinical advantages over N-terminal pro-brain natriuretic peptide, researchers report.
Johns Hopkins Medicine researchers report that rising blood levels of a protein called hematoma derived growth factor (HDGF) are linked to the increasing severity of pulmonary arterial hypertension, a form of damaging high blood pressure in the lungs.
Serum asymmetric dimethylarginine may be an effective non-invasive screening biomarker for systemic sclerosis-related pulmonary arterial hypertension, study findings indicate.
Final DASISION study findings confirm dasatinib to be an effective, long-term treatment for patients with a new diagnosis of chronic phase-chronic myeloid leukaemia.
Echocardiography re-assessment of right ventricular function after targeted therapy is sufficient to predict subsequent prognosis in patients with pulmonary arterial hypertension, say researchers.
Patients who develop pulmonary arterial hypertension as a consequence of systemic sclerosis have poorer right ventricular functional reserve than those with idiopathic disease, research published in Circulation shows.
Pulmonary hypertension is an abnormal elevation of pressure in the pulmonary circulation that results in stress on the heart and remodeling of blood vessels in the lung.
Plasma levels of endothelial progenitor cells are elevated in patients with pulmonary arterial hypertension, say researchers.
The results of a meta-analysis show the adverse impact pulmonary hypertension has on the walking stamina of patients with systemic sclerosis.